Catabasis Pharma (CATB) Tops Q4 EPS by 7c, Beats on Revenues

Note: EPS may not be comparable

Catabasis Pharma (NASDAQ: CATB) reported Q4 EPS of ($0.24), $0.07 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $130 thousand.

For earnings history and earnings-related data on Catabasis Pharma (CATB) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance